# Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

Study · id `cardio:ct-nct01760291` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01760291](<https://clinicaltrials.gov/study/NCT01760291>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01760291

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 576 participants.

## Technical summary

Registry record NCT01760291. Allocation not applicable; no masking; primary purpose prevention. Start 2012-09 (registry gives no type); primary completion 2019-04 (actual). Results posted on 2021-11-24.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 576 participants (enrolled count; ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Start date: 2012-09 (registry gives no type) (ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Primary completion: 2019-04 (actual) (ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Completion: 2019-04 (actual) (ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Results first posted: 2021-11-24 (ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01760291, source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01760291-2022-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
- Acronym: CAP2
- Condition: Atrial Fibrillation
- Intervention (Device): WATCHMAN LAA Closure Technology
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 6e066686d4d039bbe6b4da2f92c353009475271115671322a3e9449e32a9c0b8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
